Scope of nanotechnology in ovarian cancer therapeutics

被引:33
作者
Yallapu, Murali M. [1 ]
Jaggi, Meena [1 ,2 ,3 ]
Chauhan, Subhash C. [1 ,2 ,3 ]
机构
[1] Sanford Res USD, Canc Biol Res Ctr, Sioux Falls, SD 57104 USA
[2] Univ S Dakota, Sanford Sch Med, Dept Obstet & Gynecol, Sioux Falls, SD 57105 USA
[3] Univ S Dakota, Sanford Sch Med, Basic Biomed Sci Div, Sioux Falls, SD 57105 USA
关键词
BLOCK-COPOLYMER MICELLES; BIODEGRADABLE POLYMERIC MICELLES; DRUG-DELIVERY; MAGNETIC NANOPARTICLES; ANTITUMOR-ACTIVITY; POLY(ETHYLENE GLYCOL); LUNG-CANCER; PHASE-II; DOXORUBICIN; CISPLATIN;
D O I
10.1186/1757-2215-3-19
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This review describes the use of polymer micelle nanotechnology based chemotherapies for ovarian cancer. While various chemotherapeutic agents can be utilized to improve the survival rate of patients with ovarian cancer, their distribution throughout the entire body results in high normal organ toxicity. Polymer micelle nanotechnology aims to improve the therapeutic efficacy of anti-cancer drugs while minimizing the side effects. Herein, different types of polymer micelle technology based nanotherapies such as PLGA, polymerosomes, acid cleavable, thermosensitive, pH sensitive, and cross-linked micelles are introduced and structural differences are explained. Additionally, production methods, stability, sustainability, drug incorporation and drug release profiles of various polymer micelle based nanoformulations are discussed. An important feature of polymer micelle nanotechnology is the small size (10-100 nm) of particles which improves circulation and enables superior accumulation of the therapeutic drugs at the tumor sites. This review provides a comprehensive evaluation of different types of polymer micelles and their implications in ovarian cancer therapeutics.
引用
收藏
页数:10
相关论文
共 98 条
  • [1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials
    Aabo, K
    Adams, M
    Adnitt, P
    Alberts, DS
    Athanazziou, A
    Barley, V
    Bell, DR
    Bianchi, U
    Bolis, G
    Brady, MF
    Brodovsky, HS
    Bruckner, H
    Buyse, M
    Canetta, R
    Chylak, V
    Cohen, CJ
    Colombo, N
    Conte, PF
    Crowther, D
    Edmonson, JH
    Gennatas, C
    Gilbey, E
    Gore, M
    Guthrie, D
    Kaye, SB
    Laing, AH
    Landoni, F
    Leonard, RC
    Lewis, C
    Liu, PY
    Mangioni, C
    Marsoni, S
    Meerpohl, H
    Omura, GA
    Parmar, MKB
    Pater, J
    Pecorelli, S
    Presti, M
    Sauerbrei, W
    Skarlos, DV
    Smalley, RV
    Solomon, HJ
    Stewart, LA
    Sturgeon, JFG
    Tattersall, MHN
    Wharton, JT
    Huinink, WWT
    Tomirotti, M
    Torri, W
    Trope, C
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (11) : 1479 - 1487
  • [2] IMPACT OF DOXORUBICIN ON SURVIVAL IN ADVANCED OVARIAN-CANCER
    AHERN, RP
    GORE, ME
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 726 - 732
  • [3] Peptide drug carrier: studies on incorporation of vasopressin into nano-associates comprising poly(ethylene glycol)-poly(l-aspartic acid) block copolymer
    Aoyagi, T
    Sugi, K
    Sakurai, Y
    Okano, T
    Kataoka, K
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) : 237 - 242
  • [4] Relapsed ovarian cancer: Challenges and management strategies for a chronic disease
    Armstrong, DK
    [J]. ONCOLOGIST, 2002, 7 : 20 - 28
  • [5] Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change
    Bae, Y
    Fukushima, S
    Harada, A
    Kataoka, K
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (38) : 4640 - 4643
  • [6] In vivo antitumor activity of the folate-conjugated pH-Sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments
    Bae, Younsoo
    Nishiyama, Nobuhiro
    Kataoka, Kazunori
    [J]. BIOCONJUGATE CHEMISTRY, 2007, 18 (04) : 1131 - 1139
  • [7] Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
    Baetz, T
    Belch, A
    Couban, S
    Imrie, K
    Yau, J
    Myers, R
    Ding, K
    Paul, N
    Shepherd, L
    Iglesias, J
    Meyer, R
    Crump, M
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (12) : 1762 - 1767
  • [8] Fluorescence-modified superparamagnetic nanoparticles:: Intracellular uptake and use in cellular imaging
    Bertorelle, Franck
    Wilhelm, Claire
    Roger, Jacky
    Gazeau, Florence
    Menager, Christine
    Cabuil, Valerie
    [J]. LANGMUIR, 2006, 22 (12) : 5385 - 5391
  • [9] TREATMENT OF ADVANCED OVARIAN-CANCER - A RANDOMIZED TRIAL COMPARING ADRIAMYCIN OR 4'-EPI-ADRIAMYCIN IN COMBINATION WITH CISPLATIN AND CYCLOPHOSPHAMIDE
    BEZWODA, WR
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (01): : 26 - 29
  • [10] Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs
    Bontha, Satya
    Kabanov, Alexander V.
    Bronich, Tatiana K.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 114 (02) : 163 - 174